BRILLEVE tablett Eesti - eesti - Ravimiamet

brilleve tablett

sandoz pharmaceuticals d.d. - gestodeen+etünüülöstradiool - tablett - 0,075mg+0,02mg 63tk; 0,075mg+0,02mg 126tk; 0,075mg+0,02mg 21tk

MEDOCLAV suukaudse suspensiooni pulber Eesti - eesti - Ravimiamet

medoclav suukaudse suspensiooni pulber

medochemie limited - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 70ml 1tk; 80mg+11,4mg 1ml 140ml 1tk

AUGMENTIN suukaudse suspensiooni pulber Eesti - eesti - Ravimiamet

augmentin suukaudse suspensiooni pulber

glaxosmithkline (ireland) limited - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 70ml 1tk

BRILLEVE tablett Eesti - eesti - Ravimiamet

brilleve tablett

sandoz pharmaceuticals d.d. - gestodeen+etünüülöstradiool - tablett - 0,075mg+0,03mg 126tk; 0,075mg+0,03mg 21tk

JULIPERLA tablett Eesti - eesti - Ravimiamet

juliperla tablett

actavis group ptc ehf. - gestodeen+etünüülöstradiool - tablett - 75mcg+30mcg 21tk 126tk; 75mcg+30mcg 21tk 21tk; 75mcg+30mcg 21tk 63tk

AUGMENTIN FRUIT suukaudse suspensiooni pulber Eesti - eesti - Ravimiamet

augmentin fruit suukaudse suspensiooni pulber

first pharma oÜ - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 140ml 1tk; 80mg+11,4mg 1ml 70ml 1tk; 80mg+11,4mg 1ml 35ml 1tk

Comirnaty Euroopa Liit - eesti - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

AUGMENTIN FRUIT suukaudse suspensiooni pulber Eesti - eesti - Ravimiamet

augmentin fruit suukaudse suspensiooni pulber

ideal trade links uab - amoksitsilliin+klavulaanhape - suukaudse suspensiooni pulber - 80mg+11,4mg 1ml 70ml 1tk

Inpremzia Euroopa Liit - eesti - EMA (European Medicines Agency)

inpremzia

baxter holding b.v. - insulin human (rdna) - diabeet mellitus - diabeetis kasutatavad ravimid - inpremzia is indicated for the treatment of diabetes mellitus.

CEFUROXIME VENUS PHARMA süste-/infusioonilahuse pulber Eesti - eesti - Ravimiamet

cefuroxime venus pharma süste-/infusioonilahuse pulber

venus pharma gmbh - tsefuroksiim - süste-/infusioonilahuse pulber - 750mg 1tk